FDA Gives Approval for Weekly Shot of Bydureon in Treatment of Type 2 Diabetes

by Savitha C Muppala on  January 31, 2012 at 3:52 PM Diabetes News
RSS Email Print This Page Comment bookmark
Font : A-A+

The FDA has given the approval for Bydureon, which is the first weekly treatment for Type 2 Diabetes.
 FDA Gives Approval for Weekly Shot of Bydureon in Treatment of Type 2 Diabetes
FDA Gives Approval for Weekly Shot of Bydureon in Treatment of Type 2 Diabetes

The drug, an injection, is actually a long-acting form of Byetta. This shot can be used in combination with diet and exercise to improve blood sugar control among people with Type 2 diabetes.

Bydureon, is manufactured by Alkermes PLC and Amylin Pharmaceuticals Inc. Initially the FDA had not approved this drug as there were concerns that it might increase the risk of heart problems. As part of the new approval, the FDA has asked the organization to conduct a study to gauge whether the drug actually elevates risk of heart disease.

John Buse, MD, PhD, professor of medicine, director of the Diabetes Care Center, and chief of the division of endocrinology at the University Of North Carolina School Of Medicine in Chapel Hill said, "With Bydureon, U.S. physicians and patients can now choose a therapy that offers continuous blood sugar control in just one dose per week."

Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Otitis Media 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive